Welcome to our dedicated page for Cameco SEC filings (Ticker: CCJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Cameco Corporation (CCJ) SEC filings, where the company furnishes its U.S. regulatory disclosures as a foreign private issuer. Cameco files an annual report on Form 40-F, which includes its audited annual financial statements prepared in accordance with IFRS, management’s discussion and analysis (MD&A), and its Canadian annual information form. These documents outline segment performance for Uranium, Fuel Services and Westinghouse, along with risk factors and other corporate information.
Between annual reports, Cameco submits Form 6-K current reports to furnish press releases, quarterly MD&A, condensed consolidated interim unaudited financial statements and officer certifications under the Sarbanes-Oxley Act. Recent 6-K filings listed in the input include exhibits such as quarterly financial statements, MD&A for periods ended June 30 and September 30, 2025, press releases on operational updates, long-term contracts and strategic partnerships, and certifications from the chief executive officer and chief financial officer.
For investors analyzing Cameco’s uranium and nuclear fuel business, the 40-F and 6-K filings are primary sources for details on segment results, production volumes, long-term contracting, non-IFRS measures like adjusted net earnings and adjusted EBITDA, and disclosures about joint ventures such as JV Inkai. The filings also document Cameco’s equity-accounted investment in Westinghouse Electric Company, including its share of Westinghouse’s adjusted EBITDA and net earnings or losses, and information about projects in which Westinghouse participates.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify changes in production outlook, contract commitments, or segment performance without reading every page. Users can review annual Form 40-F reports, interim 6-Ks, and related exhibits, and then rely on AI-generated overviews to understand how Cameco describes its financial condition, operational plans and exposure across the nuclear fuel cycle.
A holder of CCJ common shares filed a Rule 144 notice to sell 4,000 common shares on the NYSE, with an aggregate market value of $400,680.00. The filing lists 435,457,978 shares of this class as outstanding, which provides context for the size of the planned sale. The shares to be sold were acquired on 03/03/2023 through the vesting of a long-term incentive (LTI) award, and the payment method is described as cash. The approximate date of sale is given as 01/05/2026, indicating an intention to dispose of these shares on or around that date under Rule 144.
A shareholder has filed a notice of proposed sale of Cameco Corporation common shares under Rule 144. The filing covers the planned sale of 50,000 common shares, with an indicated aggregate market value of $4,928,000.00. These shares are to be sold on the NYSE through Solium Financial Inc. on or about 01/02/2026. The issuer had 435,457,158 common shares outstanding at the time referenced.
The 50,000 shares to be sold were acquired on 01/02/2026 via a stock option exercise from Cameco Corporation, paid in cash. The filing also notes that the same seller, Timothy S. Gitzel, sold 50,000 common shares on 12/19/2025 for gross proceeds of $4,499,500.00 during the prior three-month period.
Cameco Corporation shareholder plans NYSE sale after option exercise
A shareholder of Cameco Corporation has filed notice of a planned sale of 50,000 common shares through broker Solium Financial Inc. on the NYSE, with an approximate sale date of 12/19/2025. The filing lists an aggregate market value of $4,499,500.00 for the shares to be sold. These shares were acquired on 12/19/2025 via a stock option exercise from Cameco Corporation, paid in cash for 50,000 shares. The filing notes that 435,407,158 common shares were outstanding, providing context for the size of the planned sale.
Cameco Corporation (CCJ) filed a Form 144 disclosing a proposed sale of 19,460 common shares with an aggregate market value of $1,680,000. The filing shows the shares represent part of the issuer's outstanding common stock of 435,387,448 shares and names the intended sale date as 09/15/2025 on the NYSE. The shares were acquired on 09/15/2025 through a stock option exercise from Cameco Corporation and payment was in cash. The filer reports no securities sold during the past three months and includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Cameco Corporation (CCJ) notice: an individual intends to sell 500 common shares on the NYSE through Solium Financial on 09/10/2025 for an aggregate market value of $39,735. The shares were acquired from long‑term incentive vesting in 2018–2019 (129, 184, and 187 shares on specific vesting dates) with cash payment at acquisition. The filer reports no securities sold in the past three months and affirms they are not aware of any undisclosed material adverse information about the issuer. This form is a Rule 144 notice of proposed sale and documents the planned transaction and acquisition history.